Abstract. Accumulating evidence indicates that aberrant expression of microRNAs is involved in tumorigenesis, tumor progression and response to therapy. is an important cancer-associated RNA that is downregulated in multiple types of cancer. In the present study, the potential effects of and underlying molecular mechanism for miR-375 in esophageal cancer were investigated. The expression of miR-375 in paired esophageal squamous cell carcinoma (ESCC) and non-tumor tissues from 10 patients was quantified using the reverse transcription-quantitative polymerase chain reaction. The miR-375 levels in the ESCC cell line EC109 and a normal esophageal epithelial cell line, Het-1A, were also detected. The effect of miR-375 on ESCC cell growth and invasion was determined using Cell Counting kit-8, flow cytometry and invasion assays. A luciferase assay was conducted for target identification. The results of the present study revealed that miR-375 was downregulated in ESCC tumor tissue and EC109 cells compared with normal tissue and Het-1A cells (P<0.01). Overexpression of miR-375 inhibited EC109 cell growth and invasion, and induced cell cycle arrest. In addition, metadherin (MTDH) was demonstrated to be a direct target of miR-375 (P<0.01). The overexpression of miR-375 downregulated MTDH (P<0.01), cyclin D1 (P<0.05) and vascular endothelial growth factor (P<0.01) expression, while upregulating epithelial cadherin (P<0.01) expression, which may account for its effect on ESCC cell proliferation and invasion. The results of the present study suggest that the miR-375/MTDH axis represents a target for the treatment of ESCC.
Introduction
Esophageal cancer, which includes esophageal squamous cell carcinoma (ESCC) and adenocarcinoma of the esophagus (EADC), is one of the most prevalent types of malignant tumor worldwide (1) . Esophageal cancer occupies the sixth position among malignant tumors worldwide with regard to mortality and ranks fourth in China (2) . ESCC is the most predominant esophageal cancer type in Asia (3) . Surgery, radiotherapy and chemotherapy are the typical treatments for ESCC. Due to a lack of effective clinical diagnosis methods for ESCC, it is often diagnosed in the later stages of the disease. The 5-year overall survival rate of ESCC is between 20 and 30% (4) . Investigating the mechanism of ESCC progression is essential to improve disease diagnosis, treatment and prognosis.
MicroRNAs (miRNAs) are a large class of highly conserved small non-coding RNAs that negatively regulate gene expression through binding the 3' untranslated region (3'-UTR) of target mRNAs, causing mRNA degradation and therefore repression of translation (5) . In total >1,000 miRNAs have been identified in the human genome, which may regulate the expression of <30% of all protein-coding genes (6) . Numerous studies have identified that aberrant expression of miRNAs is associated with tumorigenesis, tumor progression and response to therapy (7) . miR-375 was initially characterized as a pancreatic islet-specific miRNA, and it regulates glucose homeostasis and glucose-induced insulin secretion (8, 9) . Further miRNA expression profiling studies revealed that miR-375 is downregulated in multiple types of cancer and acts as a tumor suppressor. For example, miR-375 was demonstrated to repress gastric cancer growth by targeting Janus kinase 2 (10) . It has also been reported that miR-375 inhibits the proliferation and invasion of human squamous cervical cancer cells by repressing transcription factor SP1 (11) . In ESCC, miR-375 is one of the most frequently downregulated miRNAs (10) . However, the tumor suppression mechanism of miR-375 in ESCC has not been fully elucidated.
In the present study, it was identified that miR-375 is downregulated in ESCC tumor tissue and the ESCC cell line EC109. It was also identified that miR-375 acts as a tumor suppressor in EC109 cells, and that metadherin (MTDH) is a direct target. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total miRNA was extracted using an miRNeasy kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's protocol. RNA was converted into cDNA using an miScriptRT kit (Qiagen GmbH), according to the manufacturer's protocol. qPCR was performed using an miScript SYBR Green PCR kit (Qiagen GmbH) in an ABI 7,500 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). PCR reactions were run at 95˚C for 10 min, followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min. The detected expression of miRNAs was normalized using small nuclear RNA U6 (U6) as an endogenous control. miR-375 and U6 primers (miR-375 forward, 5'-gcagatttgttc gttcggctc-3' and reverse, 5'-gtgcagggtccgaggt-3'; and U6 forward, 5'-ctcgcttcggcagcaca-3' and reverse 5'-aacgcttca cgaatttgcgt-3') were purchased from Changsha Yingrun Biotechnology Co. Ltd. The RT-qPCR assays were performed in triplicate and the change in expression level was calculated using the 2 -ΔΔCq method (ABI 7500 Software v2.0.1; Applied Biosystems; Thermo Fisher Scientific, Inc.) (12) .
Proliferation assays. A Cell Counting kit-8 (CCK-8; Beyotime Institute of Biotechnology, Haimen, China) assay was used to measure cell proliferation. A total of 2x10 4 cells/well were plated in 96-well plates and cultured under the aforementioned conditions. Cell proliferation was monitored each day. To allow cell counting, 10 µl CCK-8 reagent was added to each well and the plates were incubated at 37˚C for 2 h. The absorbance values were subsequently measured at 450 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Each experiment was performed in triplicate.
Transfection of miR-375 mimic. The miR-375 mimic (sense, 5'-uuuguucguucggcucgcguga-3' and antisense, 5'-acgcgagcc gaacgaacaaauu-3') and a negative control (NC; sense, 5'-uuc uccgaacgugucacgutt-3' and antisense, 5'-acgugacacguucgg aga att-3') were purchased from GenePharm (Shanghai,China). Cells were plated at 3x10 5 per well in 6-well plates and cultured for 24 h. The cells were subsequently transfected with miR-375 mimic or NC RNA, to a final concentration of 75 nM, using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) and FBS-free Opti-MEM medium (Gibco; Thermo Fisher Scientific, Inc.). After 6 h, the medium was replaced with DMEM containing 10% FBS.
Flow cytometric analysis of apoptosis. Apoptotic cells were measured using an Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection kit (Nanjing KeyGen Biotech Co., Ltd, Nanjing, China). The cell samples were harvested using 0.25% EDTA-free trypsin after 48 h of incubation, washed twice with ice-cold PBS and resuspended in 500 µl binding buffer. Cells were incubated with 5 µl annexin V-FITC-labeled specific antibodies (from the apoptosis detection kit) and 5 µl propidium iodide (PI) for between 15 and 20 min in the dark, and detected using a FACSAria flow cytometer and FASCDiva 4.1 software (BD Biosciences, Franklin Lakes, NJ, USA). Each experiment was performed in triplicate.
Cell cycle assays. Following transfection with miR-375 mimic or NC, the cell samples were harvested as aforementioned and fixed with 75% ethanol at 4˚C overnight. The cells were washed in ice-cold PBS and treated with RNase I and Triton-X-100, followed by PI staining for 30 min in the dark. Finally, cells were washed and resuspended in PBS. Cell cycle distributions were detected using a BD Biosciences FACSAria flow cytometer.
Invasion assays. The invasiveness of cells was determined using a Transwell system [24-well plate, 8 µm pore polyethylene terephthalate (PET) membrane; Corning Incorporated, Corning, NY, USA]. The PET membrane was coated with Matrigel (dilution, 1:5; BD Biosciences) in FBS-free DMEM. Following transfection, the cell samples were harvested as aforementioned and resuspended in FBS-free DMEM, for seeding in the upper chamber. DMEM containing 10% FBS was added to the lower chamber. Following incubation at 37˚C for 24 h, cells that appeared on the lower surface of the membrane were fixed with methanol for 15 min at 4˚C, then stained with 0.1% crystal violet solution and counted under a light microscope.
Construction of vector and luciferase reporter assay. The 3'-UTR of the MTDH gene (positions 1454-1461) was predicted to be complementary to the sequence of miR-375 according to an analysis using the miRNA target gene prediction database TargetScan 7.1 (13) . Fragments of sequence from wild-type and mutant MTDH 3'-UTR were amplified by PCR and cloned into a pYr-MirTarget luciferase vector (Changsha Yingrun Biotechnology Co. Ltd.), designated pYr-MTDH-3U and PYr-MTDH-3Umt, respectively. The primers for the wild-type 3'-UTR, containing XhoI and NotI restriction sites, were as follows: Forward, 5'-ccgctcgagtgtggcgccaagaacgaa-3', and reverse, 5'-aaagcggccgcatactgccatgttcctgaa-3'. The primers for the mutant 3'-UTR were as follows: Forward, 5'-ttgtcagac taggaaagctaaaaaaatggttttgctgaa-3'; reverse, 5'-ttcagcaaaactaaa accatttttttagctttcctagtctgacaa-3'. HEK293 cells (American Type Culture Collection, Manassas, VA, USA) were plated into a 96-well plate and co-transfected with 100 ng pYr-MTDH-3U or pYr-MTDH-3Umt and miR-375 mimic or NC (75 nM) using Lipofectamine 2000. Luciferase activity was determined using a Dual-Luciferase Reporter Assay kit (Promega Corporation, Madison, WI, USA), according to the manufacturer's protocol. Each experiment was performed in triplicate.
Western blot analysis. Cells were harvested and homogenized with lysis buffer (Beyotime Institute of Biotechnology) 48 h post-transfection. Protein concentrations were measured using a BCA Protein Assay kit (Beyotime Institute of Biotechnology). Proteins (between 30 and 50 µg) were separated by SDS-PAGE (10% gel) and transferred onto nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). Subsequent to blocking with 5% skimmed milk powder at room temperature for 2 h, the membranes were incubated with primary antibodies specific to MTDH (catalog no., 14065S), vascular endothelial growth factor C (VEGF-C; catalog no., 2445S), cyclin D1 (catalog no., 2978T), epithelial (E-) cadherin (catalog no., 3195S) and β-actin (catalog no., 3700S) (all dilution, 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA). The membranes were then incubated with corresponding horseradish peroxidase-conjugated secondary antibodies (goat anti-mouse secondary antibody for β-actin; dilution, 1:5,000; catalog no., sc-2005 or mouse anti-rabbit secondary antibody for MTDH, VEGF-C, cyclin D1 and E-cadherin; catalog no., sc-2357; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The resulting immunoblots were quantified using ImageJ2x software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis. Data were expressed as the mean ± standard deviation from at least three independent experiments and statistically analyzed using a one-way analysis of variance test followed by Tukey's multiple comparison test or an independent sample t-test. All statistics were performed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference, and P<0.01 was considered to indicate a highly significant difference.
Results

miR-375 is downregulated in clinical esophageal cancer tissues and the ESCC cell line EC109.
The level of miR-375 in clinical esophageal carcinoma and adjacent non-tumor tissues from 10 ESCC patients were measured using RT-qPCR. The results revealed that the miR-375 level was significantly decreased in tumor tissues compared with in non-tumor tissues ( Fig. 1A; P<0.01) . Additionally, miR-375 expression in the ESCC cell line EC109 was significantly downregulated compared with that in Het-1A, a normal human esophageal endothelial cell line (Fig. 1B, P<0.01) . These results suggested that downregulation of miR-375 may be associated with the pathogenesis of esophageal cancer.
miR-375 suppresses cell growth and induces cell cycle arrest in EC109 cells.
To explore the roles of miR-375 in esophageal cancer progression, EC109 cells were transfected with miR-375 mimic or a NC. Cell proliferation rate, the proportion of apoptotic cells and cell cycle distribution were measured. Overexpression of miR-375 by miR-375 mimic transfection was confirmed using RT-qPCR ( Fig. 2A) . miR-375 overexpression significantly inhibited the proliferation of EC109 cells (Fig. 2B) . Flow cytometric analysis revealed that overexpression of miR-375 modulated the cell cycle by inducing G1 arrest (Fig. 2C) . No significant difference between the NC and miR-375 mimic group in the rate of apoptosis was identified (Fig. 2D) . These results suggested that the overexpression of miR-375 inhibited cell proliferation through triggering cell cycle arrest rather than apoptosis.
miR-375 suppresses invasion in EC109 cells. EC109 cells
transfected with miR-375 mimic or an NC were analyzed using Transwell invasion assays. As presented in Fig. 3 , overexpression of miR-375 repressed the invasive ability of EC109 cells by ~67% compared with the NC group (P<0.01).
MTDH is a direct target gene of miR-375.
To further explore the molecular mechanism of miR-375 in ESCC progression, computational algorithms were applied (using TargetScan) to predict potential target mRNAs of miR-375. It was identified that the MTDH mRNA 3'-UTR contained highly conserved binding sites for miR-375 (Fig. 4A) . Dual-luciferase assays were performed to confirm this prediction. HEK293 cells were co-transfected with pYr-MTDH-3U and miR-375 mimic. The assessment of luciferase activity demonstrated that miR-375 mimic significantly decreased the luciferase activity of pYr-MTDH-3U compared with the NC (Fig. 4B ; P<0.01). No significant difference in the luciferase activity of pYr-MTDH-3Umt was identified (Fig. 4C) . miR-375 mimic downregulated the expression of MTDH in EC109 cells (P<0.01), further confirming that MTDH is a target gene of miR-375. The expression of the MTDH downstream protein VEGF-C (P<0.01) and cell cycle regulator cyclin D1 (P<0.05) were decreased by miR-375 mimic (Fig. 4D) . By contrast, miR-375 mimic significantly upregulated expression of the epithelial marker E-cadherin ( Fig. 4D; P<0 .01), which may inhibit tumor cell epithelial-mesenchymal transition (EMT) and invasion (14) .
Discussion
ESCC has a poor prognosis and high mortality rate (2) . Cancer metastasis is the primary cause of cancer-associated mortality; therefore, preventing metastasis may be an effective strategy for cancer therapy. A number of studies have provided novel insights into the underlying molecular mechanism of regulation of gene expression by miRNAs. It has been reported that the aberrant expression of miRNA is associated with tumorigenesis, tumor progression, cancer prognoses and response to therapy (7, 15, 16) . In the present study, it was demonstrated that miR-375 was downregulated in ESCC tumor tissue samples and the ESCC cell line EC109 compared with non-tumor tissues and Het-1A, a normal esophageal endothelial cell line, respectively. Furthermore, overexpression of miR-375 in EC109 cells was demonstrated to inhibit cell proliferation and invasion, and induce cell cycle arrest. MTDH was identified as a target gene of miR-375; the results of the present study indicate that miR-375 acts as a tumor suppressor in EC109 cells by modulating the expression of MTDH.
Previous studies have identified several miRNAs suitable for use in distinguishing ESCC from non-tumor tissue. Guo et al (4) reported four miRNAs (miR-100, -99a, -29c and -140) that were downregulated and three miRNAs (miR-25, -424 and -151) that were upregulated in ESCC. Yan et al (17) confirmed that miR-340 is significantly downregulated in ESCC and inhibits ESCC cell growth and invasion by targeting phosphoserine aminotransferase 1. miR-204 was demonstrated to repress EC109 EMT and invasion by targeting box protein M1 (18) . In addition, the circulating levels of miR-21 and miR-375 in patients with ESCC may act as reliable prognostic markers for ESCC (19) . It has been demonstrated that miR-375 predominantly serves as a tumor suppressor, particularly in tumors of the digestive tract (10) . In hepatocellular carcinoma, ectopic expression of miR-375 decreases cell growth and invasion, and induces G1 arrest and apoptosis (20) . miR-375 has been reported as one of the most frequently downregulated miRNAs in esophageal cancer (21) . Similarly, in the present study, it was demonstrated that miR-375 was significantly decreased in ESCC tumor tissue and the ESCC line EC109. Overexpression of miR-375 in EC109 repressed cell growth and invasion; however, it did not induce apoptosis in EC109 cells. miR-375-induced G1 cell cycle arrest was the primary cause for the inhibition of EC109 cell proliferation.
Although several studies have explored the role of miRNAs in esophageal cancer, the identified potential targets require further confirmation. For example, overexpression of miR-145, -133a or -133b in ESCC may inhibit cell proliferation and invasion; they all may repress the expression of Fascin homolog 1 (22) . miR-375 inhibits ESCC cell proliferation through targeting insulin-like growth factor receptor 1 and 3-phosphoinositide-dependent protein kinase-1, which are involved in the potentially carcinogenic phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway (10) . To investigate the mechanism of miR-375 function in ESCC cells, computational algorithms were used to predict possible target mRNAs of miR-375. The intersection of algorithms and a luciferase reporter assay indicated that MTDH was a target gene of miR-375. MTDH was originally identified as an oncogene (23) upregulated in numerous types of malignancy, including breast cancer, neuroblastoma, non-small cell lung cancer and cancers of the digestive tract (24) (25) (26) . A number of studies have demonstrated that the upregulation of MTDH promotes tumor progression through modulating signaling pathways including the PI3K/AKT, Wnt/β-catenin and nuclear factor κB signaling pathways (24) . In the present study, overexpression of miR-375 in EC109 cell significantly decreased the expression of MTDH.
To further investigate the mechanism of miR-375 on tumor growth and invasiveness, the expression levels of VEGF-C, E-cadherin and cyclin D1 were examined. The results demonstrated that cyclin D1 and VEGF-C were downregulated, whereas E-cadherin was upregulated in miR-375-overexpressing EC109 cells. The majority of tumors and metastases begin as avascular masses limited in size (27) , therefore VEGF-C, an inducer of angiogenesis, is a critical factor for tumor growth and development (28) . It has been confirmed that MTDH can directly upregulate VEGF-C expression by enhancing VEGF-C promoter activity and activating the PI3K/AKT signaling pathway (29, 30) . Cyclin D1 is essential for G1 phase progression and is frequently overexpressed in a broad range of human cancers (31) . The overexpression of MTDH was observed in chronic lymphocytic leukemia and was identified to be associated with the Rai stage classification. Inhibition of MTDH expression resulted in decreased levels of cyclin D1 via suppression of the Wnt/β-catenin signaling pathway (32) . The epithelial marker E-cadherin serves a key role in EMT; its expression represses tumor invasion and metastasis (33) . Li et al (34) have reported that overexpression of MTDH could promote EMT via downregulating E-cadherin and increasing other EMT indicators. This demonstrates the involvement of MTDH in tumorigenesis and supports the results of the present study, suggesting that downregulation of miR-375 may contribute to ESCC tumorigenesis via the resulting upregulation of MTDH.
In summary, the present study has revealed that miR-375 is underexpressed in ESCC tumor tissue samples and the ESCC cell line EC109, compared with normal tissue and cells. miR-375 has been demonstrated to act as a tumor suppressor in ESCC cells that inhibited cell proliferation and invasion by repressing the expression of its direct target MTDH, an oncogene associated with tumorigenesis in numerous types of cancer. Therefore, the miR-375/MTDH axis may represent a potential target for the treatment of ESCC.
